Get the Daily Brief
Latest Biotech News
NK cell infusions show promise in liver cancer post‑transplant trial
A phase I study explored adoptive Natural Killer (NK) cell infusions for hepatocellular carcinoma (HCC) in patients with recurrent disease after liver transplantation. Investigators reported...
SPARK trial: sitravatinib plus tislelizumab shows activity in recurrent/metastatic TNBC
Interim results from the SPARK phase II trial report clinical activity for the combination of sitravatinib, a spectrum kinase inhibitor, with tislelizumab, an anti‑PD‑1 antibody, in patients with...
EU launches FAST‑EU pilot to accelerate multinational clinical trials
The European Union unveiled FAST‑EU, a voluntary pilot designed to shorten startup timelines for multinational clinical trials to a maximum 70 days for certain studies. The pilot will fast‑track...
New products roll: Tempus AI, Navinci Diagnostics, Parse Biosciences and Zepto Life launch clinical tools
Several commercial product launches broaden diagnostic and spatial biology toolsets for translational research and clinical labs. Tempus AI introduced Paige Predict, an AI suite that estimates 123...
Erasca closes upsized offering — $258.8M raised
Erasca announced the closing of an upsized public offering that generated approximately $258.8 million in gross proceeds. The clinical-stage precision oncology company, focused on RAS/MAPK pathway...
Corxel banks $287M to push oral GLP‑1
Corxel Pharmaceuticals closed a $287 million Series D financing to advance CX‑11, an oral small‑molecule GLP‑1 receptor agonist, through U.S. and global phase II trials and to prepare for phase...
Sanofi presses forward: filings eyed for amlitelimab after mixed Phase 3
Sanofi said it will pursue regulatory submissions for amlitelimab in atopic dermatitis despite mixed results across its Phase 3 program. The company cited the totality of the data and signaled...
Wegovy pill takes off: prescriptions surge in second week
Novo Nordisk reported a rapid uptake of its oral Wegovy launch, with prescriptions rising roughly 500% in the product’s second week and prescriptions surpassing 18,000 in the same period. The...
Federal Circuit remands Guardant patent case to appeals board
The U.S. Court of Appeals for the Federal Circuit remanded a patent infringement dispute involving Guardant Health, TwinStrand Biosciences, and the University of Washington back to the Patent...
Protein‑sequencing start‑up Encodia shutters — assets headed to auction
Encodia, a San Diego protein‑sequencing company that developed a DNA‑tagging peptide readout called ProteoCode, ceased operations and initiated an assignment for the benefit of creditors. The...
Venter‑backed Diploid Genomics launches with seed funding
A new spinout, Diploid Genomics, cofounded by J. Craig Venter, launched with undisclosed seed funding from Healthier Capital. The company plans an AI‑driven genomics analytics platform that...
EU rolls out FAST‑EU pilot: 70‑day target to start multinational trials
The European Union launched FAST‑EU, a voluntary one‑year pilot designed to accelerate multinational clinical trial start‑up timelines. The program sets a maximum 70‑day (10‑week) timeline from...
FDA drafts guidance for cuffless blood‑pressure monitors — oversight tightens
The FDA’s Center for Devices and Radiological Health released a draft guidance proposing regulatory expectations for cuffless blood‑pressure monitoring devices. The agency aims to clarify...
F2G plans olorofim FDA resubmission after collecting Phase 3 data
F2G’s chief executive said the antifungal developer plans to resubmit olorofim to the FDA after completing Phase 3 data collection expected this June. Olorofim, an oral antifungal targeting...
Erasca raises $258.8m in upsized offering
Erasca closed an upsized public offering that generated roughly $258.8 million in gross proceeds, the company said in a Globe Newswire filing. The financing sold 25.875 million shares at $10.00...
Protein sequencing startup Encodia folds... auctions lab equipment
Encodia, a San Diego protein‑sequencing company that developed a DNA‑tagging approach called ProteoCode, ceased operations late last year and is liquidating lab assets, GenomeWeb reported. The...
Appeals court remands Guardant patent case to PTAB – damages in flux
A U.S. appeals court remanded Guardant Health’s patent lawsuit with TwinStrand Biosciences to the Patent Trial and Appeal Board for additional validity review, potentially altering earlier jury...
Novo’s Wegovy pill surges: prescriptions jump 500% in week two
Novo Nordisk’s oral Wegovy (semaglutide) pill saw a rapid uptake in the U.S., with prescriptions reported to have increased roughly 500% in its second week on the market, analysts noted. The early...
Corxel banks $287m to advance oral GLP‑1 CX‑11
Corxel Pharmaceuticals closed a $287 million Series D to push its oral small‑molecule GLP‑1 agonist CX‑11 through U.S. and planned global Phase II trials and begin Phase III preparations. The...
Sanofi to file for amlitelimab despite mixed Phase 3 reads
Sanofi said it will pursue global regulatory submissions for amlitelimab, an OX40‑ligand (OX40L) inhibitor for atopic dermatitis, despite mixed late‑stage results across trials. Company statements...